In the fast-evolving landscape of healthcare and pharmaceuticals, the role of technology, particularly artificial intelligence (AI), is becoming increasingly prominent.
At DPharm 2023, there was a huge meeting of minds to discuss the latest innovations in clinical trials. Outsourcing Pharma was delighted to have an in-depth discussion with IQVIA’s Elan Josielewski, senior principal and head of operations, patient centered...
Compliance data generated from the documentation of interactions with HCPs can be leveraged using AI and ML to the benefit of stakeholders across the industry, according to IQVIA.
This month’s news on technology, partnerships, expansions, and more includes items from IQVIA, Almac Group, Signant Health, Lonza, and other key companies.
An expert from the trial tech firm explains how the 21st Century Cures Act and other recent regulatory advancements can elevate clinical data registries.
An expert from the trial tech company discusses tools that can prove useful for trial teams looking to avoid employee shortages plaguing other industries.
Leaders from the biotech company share advice on how such organizations can make the most of often limited resources via smart strategy and collaboration.
An expert from the health tech company explains how AI, natural language processing, and other tools can improve pharmaceutical product safety reporting.
An expert from the clinical technology solutions provider discusses some of the top challenges associated with technology adoption, and how to tackle them.
The latest news on software, manufacturing solutions, partnerships, and more includes IQVIA, TFF Pharmaceuticals, Quotient Sciences and other key companies.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.
An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
A leader from the company discusses how advanced analytical tools can be put to work to help tackle adverse event case processing and compliance issues.
Leaders from IQVIA and its Q2 Solutions division offer advice on how to deal with mobile teams, home health providers, and other aspects of virtual trials.
An epidemiologist from the healthcare data specialist offers perspective on how real-world data can help get to the heart of long-lasting COVID research.
A leader from IQVIA suggests what to look for when seeking ways to automate drug safety processes, while maintaining security and customer satisfaction.
The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.
The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90 countries.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
Two leaders from the clinical technology solutions company discuss how digital tools like eCOAs have been invaluable in facing pandemic-related challenges.
A leader from the IQVIA company explains how the boom in the volume and quality of data, and advanced analysis, can speed and streamline drug development.
The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.
In order to effectively handle collection and analysis of huge volumes of vital data, a leader from IQVIA advises bringing on people up to the challenge.
A leader from Iqvia will present an overview of artificial intelligence, machine learning and other \technology during this year’s CPhI Festival of Pharma.
A leader with the health data specialists looks at how COVID-19 has impacted the clinical research industry, and what the future of the field might look like.
The health information technology company is looking at ways to alleviate the burdens clinical trial participants face, in order to improve recruitment and retention.
Filed in 2017, Veeva Systems’ antitrust lawsuit alleges Iqvia has exacted ‘monopoly control’ restricting freedom in clinical trial software and data management.
Though pharma companies now accept the value of AI and machine learning, extra effort is required by the industry to realize the potential business and patient benefits, says Iqvia exec.
The FDA has published the second in a series of guidance documents that aim to accelerate research and the use of patient input to inform clinical development programs, says Iqvia head.
Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.
The Friends of Cancer Research, in collaboration with Iqvia and other health care research organizations, are working to determine where and when real-world data can be trusted.
Iqvia today launches its new patient portal, designed to support clinical trial participants throughout the process with a “direct connection to the clinical research environment,” says company executive.
It’s a lot more complicated than a simple technology – says Iqvia global head of virtual trials, who shares four lessons learned during a discussion at the company’s headquarters in Research Triangle Park.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Iqvia today launched a new “patient centered endpoints” solution, which captures the patient experience during clinical trials and real world studies, says SVP.
Iqvia leads the real world evidence market, which is at an inflection point, as pharma furthers its investment and vendors improve capabilities, according to a recent report.
The global oncology market last year set several records, though the industry continues to struggle with long development timelines, which in 2018 averaged 10.5 years from patent filing to regulatory approval and launch, according to a recent Iqvia report.